Nxstage Medical (NXTM) Tops Q3 EPS by 5c

Nxstage Medical (NASDAQ: NXTM) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $86.5 million versus the consensus estimate of $82.06 million.

Nxstage Medical sees FY2015 revenue of $332-333 million, versus prior guidance of $324-328 million and the consensus of $327.8 million. The Company now expects full-year net loss to be between $15 and $16 million, versus its previous guidance of $18 to $20 million, which was revised from its original guidance of $20 to $24 million.

Nxstage Medical sees Q4 2015 revenue of $86-87 million, versus the consensus of $86.0 million.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• Nike (NKE) Tops Q1 EPS by 4c
• Jabil (JBL) Tops Q4 EPS by 34c, Beats on Revenue; Offers FY Guidance
• Progress Software Corporation (PRGS) Tops Q3 EPS by 17c ; Offers Guidance